Loading clinical trials...
Loading clinical trials...
A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).
Conditions
Interventions
Darapladib 160 mg
Placebo
+1 more
Locations
914
United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Huntsville, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Anchorage, Alaska, United States
Start Date
December 1, 2009
Primary Completion Date
April 1, 2014
Completion Date
April 24, 2014
Last Updated
August 10, 2017
NCT07436429
NCT07429227
NCT01311323
NCT06543082
NCT06535568
NCT07032389
Lead Sponsor
GlaxoSmithKline
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions